Compare RDW & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | KYMR |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 4.7B |
| IPO Year | N/A | 2020 |
| Metric | RDW | KYMR |
|---|---|---|
| Price | $7.36 | $89.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 23 |
| Target Price | $12.67 | ★ $101.43 |
| AVG Volume (30 Days) | ★ 7.5M | 1.4M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $296,147,000.00 | $43,735,000.00 |
| Revenue This Year | $11.89 | $20.81 |
| Revenue Next Year | $43.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.87 | $19.45 |
| 52 Week High | $26.66 | $103.00 |
| Indicator | RDW | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 72.51 |
| Support Level | $5.11 | $86.23 |
| Resistance Level | $5.58 | $93.82 |
| Average True Range (ATR) | 0.50 | 4.66 |
| MACD | 0.34 | 2.34 |
| Stochastic Oscillator | 72.82 | 65.66 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.